BeiGene Announces U.S. Regulatory Filing
Labcorp Holdings Names Julia Wang Chief Financial Officer, Effective Dec. 2 >LH
Press Release: Labcorp CFO Glenn Eisenberg Announces Plans to Retire
BeiGene Has Entered Into A Settlement Agreement With MSN Pharmaceuticals And MSN Laboratories Private Resolving Patent Litigation Related To MSN's Abbreviated New Drug Application Seeking Approval To Market A Generic Version Of Brukinsa (Zanubrutinib)...
Beigene (06160) has granted stock options and restricted stock units.
Beigene (06160) announced that on November 14, 2024, the board of directors' compensation committee in accordance with 20...
U.S. stocks move: Beigene rises 3% pre-market as multiple institutions are bullish.
Grain Rice on November 19th | Beigene (BGNE.US) rose 3.09% before the market opened, to $193.49. Bocom Intl released a research report stating that Beigene's third-quarter product sales volume trend remains unchanged, with the continued expansion of the share of new patients for its core indication Zebu Tini. Total revenue increased by 28.2% year-on-year to $1.002 billion, with adjusted non-GAAP operating profit of $65.63 million, achieving positive non-GAAP operating profit for two consecutive quarters. The bank raised Beigene's H-share target price to HK$159, with catalysts about to land intensively. In addition, research reports by Soochow Securities indicated that Beigene